Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

By sjmartinez • February 24, 2023

Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. PMID: 36816342; PMCID: PMC9932343.

Tags: Dermatology, Olive View DoM, Publications

Effect of biologic use on the development of psoriatic arthritis: A population-based study

Miao KL, Huang MY, Guo L, Lung K, Armstrong AW. Effect of biologic use on the development of psoriatic arthritis: A population-based study. J Eur[...]

The Colors Beneath: More Than a Skin Condition

Yan MJ, Chou PP, Roberts AM, Jeong CY, Johnsen N, Katz A, Ma EJ, Nong Y, Armstrong AW. The Colors Beneath: More Than a Skin[...]

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study

Holtsche MM, van Beek N, Hammers CM, Vorobyev A, Kasperkiewicz M, Schumacher N, Muck P, Schmidt E. Adjuvant therapy of severe and/or refractory bullous pemphigoid[...]